HOME >> BIOLOGY >> NEWS
Recombinant Protein Immunizes Mice, Promises New Strategy Against Infection And Cancer

oy the germs circulating in the bloodstream. However, antibodies are useless when it comes to penetrating cells. The task of attacking cells infected by viruses or deformed by cancer falls to the second arm of the immune system, led by immune cells called T cells. T cells orchestrate a multi-pronged attack, and if appropriate, turn into 'killer cells,' called cytotoxic T cells or CTLs, that home in on infected cells and destroy them.

The goal of vaccine development is to produce a full-blown immune response without causing full-blown disease. However, when vaccines containing soluble proteins from the microorganisms are used to produce an immune response, the CTLs are rarely activated.

For decades, vaccine development experts have sought to find a simple and practical way to activate the killer cells or CTLs using soluble proteins, but finding a method that works has been a challenge.

"We were able to solve this problem by taking advantage of the observation that a class of proteins, called heat-shock proteins, are exceptions to the rule that soluble proteins are unable to stimulate CTL responses. In fact, heat-shock proteins are extremely potent in stimulating a CTL immune response," says Dr. Young.

Heat shock proteins, or stress proteins, are a family of proteins that cells produce in response to stress from heat, injury, germs, or toxins. Normally, these proteins act as molecular chaperones, binding to other proteins and ferrying them to and from various compartments of the cell. A few years ago, immunologists noticed that heat shock proteins are present on the surface of bacteria and are responsible for flagging the T cells and triggering the CTLs to attack.

Dr. Young and his colleagues found one particular protein from the tuberculosis bacterium, called hsp70, that could elicit powerful immune responses and could be used as an immune system booster. The special properties of hs
'"/>

Contact: Seema Kumar or Eve Nichols
kumar@wi.mit.edu, nichols@wi.mit.edu
(617) 258-5183
Whitehead Institute for Biomedical Research
25-Nov-1997


Page: 1 2 3

Related biology news :

1. Recombinant Protein Expression Lab established at CU
2. Recombinant yeast as an antifungal vaccine
3. Recombinant protein may play key role in treating immunocompromised patients
4. Virginia Tech Scientists To Evaluate Risks Associated With Release of Recombinant Organisms
5. Protein is key to fatal disorder and normal cell function
6. Protein is key for digestive function of the pancreas
7. Proteins show promise for mosquito control
8. Protein involved in childhood disorder linked to cancer
9. Protein fishing in America: The movie
10. Protein vaccine fully protects mice from lethal aerosol challenge with ricin toxin
11. Protein key to trafficking in nerve terminals

Post Your Comments:
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: